Literature DB >> 26205489

Regulation of the p53 response and its relationship to cancer.

David W Meek1.   

Abstract

p53 has been studied intensively as a major tumour suppressor that detects oncogenic events in cancer cells and eliminates them through senescence (a permanent non-proliferative state) or apoptosis. Consistent with this role, p53 activity is compromised in a high proportion of all cancer types, either through mutation of the TP53 gene (encoding p53) or changes in the status of p53 modulators. p53 has additional roles, which may overlap with its tumour-suppressive capacity, in processes including the DNA damage response, metabolism, aging, stem cell differentiation and fertility. Moreover, many mutant p53 proteins, termed 'gain-of-function' (GOF), acquire new activities that help drive cancer aggression. p53 is regulated mainly through protein turnover and operates within a negative-feedback loop with its transcriptional target, MDM2 (murine double minute 2), an E3 ubiquitin ligase which mediates the ubiquitylation and proteasomal degradation of p53. Induction of p53 is achieved largely through uncoupling the p53-MDM2 interaction, leading to elevated p53 levels. Various stress stimuli acting on p53 (such as hyperproliferation and DNA damage) use different, but overlapping, mechanisms to achieve this. Additionally, p53 activity is regulated through critical context-specific or fine-tuning events, mediated primarily through post-translational mechanisms, particularly multi-site phosphorylation and acetylation. In the present review, I broadly examine these events, highlighting their regulatory contributions, their ability to integrate signals from cellular events towards providing most appropriate response to stress conditions and their importance for tumour suppression. These are fascinating aspects of molecular oncology that hold the key to understanding the molecular pathology of cancer and the routes by which it may be tackled therapeutically.
© 2015 Authors; published by Portland Press Limited.

Entities:  

Keywords:  MDM2; p53; post-translational modification; signalling; tumour suppressor

Mesh:

Substances:

Year:  2015        PMID: 26205489     DOI: 10.1042/BJ20150517

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  109 in total

1.  Interaction of TIM4 and TIM3 induces T helper 1 cell apoptosis.

Authors:  Rong-Ti Ge; Lu Zeng; Li-Hua Mo; Ling-Zhi Xu; Huan-Ping Zhang; Hai-Qiong Yu; Min Zhang; Zhi-Gang Liu; Zhan-Ju Liu; Ping-Chang Yang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Gallid Herpesvirus 1 Initiates Apoptosis in Uninfected Cells through Paracrine Repression of p53.

Authors:  Hai Li; Qi Gao; Yuhao Shao; Bangyao Sun; Fengjie Wang; Yangyang Qiao; Nana Wang; Shengwang Liu
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

3.  Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?

Authors:  Hiroyuki Inatani; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Satoshi Yamada; Kiyofumi Asai; Takanobu Otsuka; Hiroyuki Tsuchiya
Journal:  Clin Orthop Relat Res       Date:  2017-02-02       Impact factor: 4.176

4.  The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes.

Authors:  Margot E Bowen; Jacob McClendon; Hannah K Long; Aryo Sorayya; Jeanine L Van Nostrand; Joanna Wysocka; Laura D Attardi
Journal:  Dev Cell       Date:  2019-06-06       Impact factor: 12.270

5.  Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies.

Authors:  Anneleen Steels; Adriaan Verhelle; Olivier Zwaenepoel; Jan Gettemans
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

6.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

7.  Identification of DHX36 as a tumour suppressor through modulating the activities of the stress-associated proteins and cyclin-dependent kinases in breast cancer.

Authors:  Yinduo Zeng; Tao Qin; Valentina Flamini; Cui Tan; Xinke Zhang; Yizi Cong; Emily Birkin; Wen G Jiang; Herui Yao; Yuxin Cui
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

8.  Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study.

Authors:  Jing Zhang; Jian Sun; Xiao-Long Liang; Jun-Liang Lu; Yu-Feng Luo; Zhi-Yong Liang
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

9.  Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis.

Authors:  Michael I Carr; Justine E Roderick; Hugh S Gannon; Michelle A Kelliher; Stephen N Jones
Journal:  Cell Rep       Date:  2016-08-25       Impact factor: 9.423

10.  Pteisolic acid G, a novel ent-kaurane diterpenoid, inhibits viability and induces apoptosis in human colorectal carcinoma cells.

Authors:  Shuangli Qiu; Xin Wu; Hongbo Liao; Xiaobin Zeng; Senwang Zhang; Xiaofen Lu; Xiaohong He; Xiaoqi Zhang; Wencai Ye; Hua Wu; Xiaohui Zhu
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.